

**SCIENTIFIC MEETING OF THE DUTCH SOCIETY FOR CLINICAL PHARMACOLOGY
 AND BIOPHARMACY (NVKFB) together with
 the DUTCH PHARMACOLOGICAL SOCIETY (NVF)**

**Online Hybrid meeting
 April 13rd 2021**

- 09.30 h Plenary session
Moderators: Liesbeth de Lange & Kees Kramers
- 09.45 h **Keynote Speaker 1 | Prof. dr. Hiddo Lambers Heerspink** (University Medical Center Groningen)
Moderators: Liesbeth de Lange & Kees Kramers
- 10.30 h Coffee break
- 10.45 h Morning **Parallel sessions**

Translational Pharmacology and Models <i>Moderators: Tom Schirris</i>		Evidence and education <i>Moderators: Nshunge Musheshe</i>	
10.45 h	Y. Yang, UIPS Utrecht Identification of a proximal tubule epithelial cell line Ciptec-OAT1 as a novel senescence model	10.45 h	M.J. Bakkum, AUMC Amsterdam Europe2E – The European open platform for prescribing education, a consensus study among clinical pharmacology and therapeutics teachers
11.00 h	I.R.F. van Berlo Deventer Teaching hospital & RU Groningen Binding interactions with sevelamer and polystyrene sulfonate <i>in vitro</i>	11.00 h	F. Hashemi, UU Utrecht A clinical decision support system can effectively prevent dosing errors
11.15 h	H. Marynissen, UZ Leuven TRP-mediated vascular changes on fingers in healthy volunteers – from uncovering the pathophysiology towards efficacious analgesia for peripheral neuropathy	11.15 h	N.J.L. Smeets, Radboudumc Nijmegen The level of evidence of the dosing recommendations in the Dutch pediatric formulary

11.30 h	H.J. Hijma, CHDR Leiden Comparison of two distinct 1% capsaicin formulations for use as model for sensitization in early-phase drug development	11.30 h	S.A. van Laar, LUMC Leiden Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in The Netherlands
---------	--	---------	--

11.45 h Coffee break

11.50 h Parallel program Assembly meetings

General Meetings, NVKFB	Pharmaquiz (using Zoom) PhD students/trainees: (Moderator: Ben Janssen & Tom Schirris)
--------------------------------	---

12.50 h Lunch Break

13.10 h Moderated 6 parallel **poster pitch sessions** (using Zoom, see page 4 -6 for poster session schedules)

- *Modelling & Simulation & Populations*
- *Cardiovascular, Renal & Metabolic*
- *Immunology & Oncology*
- *Neurology & Psychiatry & Pain*
- *Education & Trials*
- *PK, PD & PGx*

14.00 h Afternoon **Parallel sessions**

PK/PD/TDM <i>Moderators: Robert Rissmann</i>		Preclinical and Toxicology <i>Moderator: Marleen Kemper</i>	
14.00 h	E. Boerrigter, Radboudumc Nijmegen The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer	14.00 h	A. Marmolejo-Garza, Groningen & Utrecht Blockade of mitochondrial Calcium uptake protects neurons against ferroptosis
14.15 h	S.A.J. Buck, Erasmus MC Rotterdam Probenecid boosts endoxifen exposure in breast cancer patients using tamoxifen	14.15 h	C.A. Hoogstraten, Radboudumc Nijmegen Role of ADP/ATP carrier function in drug-induced mitochondrial dysfunction
14.30 h	M. Meeberg, Amsterdam UMC Erythrocyte methotrexate polyglutamate concentrations in patients with Crohn's	14.30 h	G. Maring, Isala Klinieken Zwolle A combination of pre-screening for DPD deficiency by geno-/phenotyping and PK-guided

	disease: towards a new therapeutic drug monitoring tool		dosing of 5-FU to prevent severe toxicity in GI-cancer patients (CombiGapp: Interim results)
14.45 h	C. Smit, LACDR Leiden Dosing recommendations for vancomycin in children and adolescents with varying levels of obesity and renal dysfunction: a pharmacokinetic study in 1892 children aged 1-18 years	14.45 h	M. Sanders, Radboudumc Nijmegen Effect of chronic oral anticoagulation on Covid-19 outcome: vitamin K antagonists versus direct oral anticoagulants

15.00 h Coffee break

15.15 h **Keynote Speaker 2 | Prof. dr. Roos Masereeuw** (Utrecht University)

Moderators: Liesbeth de Lange & Kees Kramers

16.00 h **Prize ceremony**

Moderators: Liesbeth de Lange & Kees Kramers

'NVKFB'-Thesis Award 2019 & 2020

'NVF'-Thesis award 2019 & 2020

'NVKFB'-TOP Publication Award 2019

'NVKFB' -Education Award 2020

'NVF' best poster prize

'NVKFB' best poster prize

POSTER PITCH SESSIONS (13.10 - 14.00 h)

PITCH SESSION 1			
Modelling & Simulation & Populations			
	HRS	PRESENTER	ABSTRACT TITLE
#1	13.10	Agema, Bram	Population pharmacokinetics of oxycodone and active metabolites in patients with cancer-related pain
#2	13.15	Blom, Lara	Clinical implementation of a novel model-based dosing guideline for gentamicin in neonates
#3	13.20	Bosch-Arnoldussen, Denise	Older patients' perceptions of medicines and willingness to deprescribe
#4	13.25	Budda, Divakar	Prediction of CNS target engagement of pain-relieving drugs in health and chronic pain conditions
#5	13.30	Dittrich, Anne	Quality measurement of adverse drug reaction reports in paediatric patients
#6	13.35	Eijk, Maarten van	Pharmacokinetic and pharmacodynamic modelling of different oral paclitaxel formulations co-administered with ritonavir
#7	13.40	Saleh, Mohammed	Predicting the impact of CNS pathophysiology on human brain pk: LeiCNS-PK3.0 applications
#8	13.45	Verscheijden, Laurens	Development of a PBPK model for the prediction of morphine and morphine-6-glucuronide brain permeability and analgesic effects in children
#9	13.50	Hirasawa, Makato	Expansion of LeiCNS-PK3.0 for the prediction of PK profile in brain tumors

PITCH SESSION 2			
Cardiovascular, Renal & Metabolic			
	HRS	PRESENTER	ABSTRACT TITLE
#1	13.10	Aart-van der Beek, Annemarie van der	Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease
#2	13.15	Eveleens Maarse, Boukje	Effect of hydroxychloroquine on the ECG and the cardiac ventricular repolarization – a concentration-effect analysis
#3	13.20	Heijden, Charlotte van der	Effects of dalteparin on anti-XA levels cannot be predicted in critically ill COVID-19 patients
#4	13.25	Irvine, Alasdair	A systematic review of in vitro models of drug induced kidney injury
#5	13.30	Jong, Corine de	Association between genetic variants and cisplatin-induced nephrotoxicity: a genome-wide approach and validation study
#6	13.35	Reinders, Mattheus	Survival of severe chloroquine overdose WITH CARIAC ARREST by EARLY AND prolonged intravenous lipid emulsion treatment
#7	13.40	Sablerolles, Roos	Is chronic anticoagulant use associated with intensive care admission and mortality in COVID-19? Evidence from the Covid MEDicaTion (COMET) study.
#8	13.45	Sen, Taha	Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin: results from the canvas trial
#9	13.50	Sen, Taha	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2, and KIM-1 in the canvas trial
#10	13.55	Spiegelenberg, Janneke	Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: a propensity score-matched cohort study

PITCH SESSION 3			
Immunology & Oncology			
	HRS	PRESENTER	ABSTRACT TITLE
#1	13.10	Waijer, Simke	Large between-patient variability in eGFR decline before clinical trial enrollment and impact on atrasentan's efficacy: A post-hoc analysis from the SONAR trial
#2	13.15	Goldsteen, Pien	Pluripotent stem cell derived airway cholinergic neurons for disease modelling of neuroplasticity in asthma
#3	13.20	Kicken, Mart Pepijn	The effect of body mass index on treatment outcome of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer
#4	13.25	Krens, Stefanie	Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
#5	13.30	Majernikova, N.	The role of lipoxygenase activity in ferroptotic cell death
#6	13.35	Martson, Anne-Grete	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
#7	13.40	Westende, van 't Juliette	Human ex vivo and in vivo models for inflammasome activation.
#8	13.45	Rouw, Nikki de	Hyperhydration with cisplatin does not compromise pemetrexed exposure
#9	13.50	Bernsen, Emma	Implementation of Pre-emptive Pharmacogenetic Screening in Paediatric Oncology
#10	13.55	Prins-Can, Ilona	Assessing the binding interaction of polystyrene sulfonate with Amitriptyline in Healthy Volunteers

PITCH SESSION 4			
Neurology, Psychiatry & Pain			
	HRS	PRESENTER	ABSTRACT TITLE
#1	13.10	Bet, Pierre	Therapeutic drug monitoring of psychotropics as a diagnostic tool for CYP2D6 poor metabolizer phenotype
#2	13.15	Gülave, Berfin	Human CNS drug distribution of morphine in pain conditions
#3	13.20	Kalkman, Gerard	Practice variation in chronic high-dose opioid prescribing for non-cancer pain in Dutch primary care: a retrospective database study
#4	13.25	Ruijs, Titia	A randomized, double-blind, placebo-controlled, cross-over study to determine effects of mexiletine on muscle velocity recovery cycles in healthy volunteers
#5	13.30	Ruijs, Titia	A randomized, double-blind, placebo-controlled, cross-over study to investigate effects of mexiletine and lacosamide on nerve excitability in healthy subjects
#6	13.35	Wilhelmus, Micha	Solving the crisis in psychopharmacological research: cellular-membrane(s) pharmacology to the rescue?
#7	13.40	Wit, Laura de	Disproportionality of impulse control disorders associated with dopaminergic drugs
#8	13.45	Zhang, Tong Tong	EPAC2 defines the neurotoxic effect of A β in experimental models of alzheimer's disease
#9	13.50	Zhang, Yuequ	Novel pharmacological SK2 channel modulators and their protective role in glutamate-mediated toxicity

PITCH SESSION 5			
Education & Trials			
	HRS	PRESENTER	ABSTRACT TITLE
#1	13.10	Beärda, Froukje	Unraveling suboptimal scores on the subject anticoagulation on the Dutch national pharmacotherapy test in the medical curriculum of the Erasmus medical
#2	13.15	Boer, Merel de	The effect of pemetrexed dose individualization on development of neutropenia – a budget impact analysis
#3	13.20	Coppes, Tristan	Identifying medication-related readmissions: students versus a multidisciplinary panel
#4	13.25	Dane, Aniek	How to reduce barriers to patient enrollment in phase III cancer clinical trials: views of clinicians' and pharmaceutical industry representatives
#5	13.30	Donker, Erik	The Dutch List of Essential Medicines for Medical Education, a Modified Delphi Study
#6	13.35	Kalfsvel, Laura	Increasing pharmacotherapy knowledge and skills in medical students by practicing with e-learning program P-scribe
#7	13.40	Meurs, Elsemieke	Preventable hospital readmissions within 30 days: an observational study analyzing clinical characteristics and risk factors
#8	13.45	Sallevelt, Bastiaan	Frequency and acceptance of clinical decision support system generated stopp/start signals for hospitalised older patients with polypharmacy and multimorbidity
#9	13.50	Steen, Carlijn van der	A pharmacotherapy self-assessment improves prescribing by prompting junior doctors to study further
#10	13.55	Wasylewicz, Arthur	An algorithm to identify adverse drug reactions from free text Dutch electronic hospital health record notes

PITCH SESSION 6			
PK, PD & PGx			
	HRS	PRESENTER	ABSTRACT TITLE
#1	13.10	Bayoumy, Ahmed	The Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype with 6-Thioguanine Nucleotides Levels in 316 Inflammatory Bowel Disease patients on 6- Thioguanine
#2	13.15	Donners, Anouk	A systematic review on the pharmacokinetics and associated pharmacodynamics of emicizumab in humans
#3	13.20	Ewoldt, Tim	Large variability of unbound active fraction of ceftriaxone in contrast to ciprofloxacin in plasma of critically ill patients
#4	13.25	Ghimire, Samiksha	Dried blood spot sampling to assess rifampicin pharmacokinetics among tuberculosis patients in Paraguay
#5	13.30	Gerritse, Sophie	High-dose intermittent sunitinib leads to increased tumor drug exposure associated with a favorable outcome in patients with advanced solid tumors.
#6	13.35	Heersche, Niels	Cytochrome P450 activity and the systematic balance of its cofactor iron
#7	13.40	Machiels, Julian	Population pharmacokinetics of cefuroxime in critically ill patients admitted to the ICU
#8	13.45	Vonk, Steffie	No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: a case report.
#9	13.50	Molenaar-Kuijsten, Laura	Effects of the moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib: a randomized cross-over trial in patients with breast cancer
#10	13.55	Ockeloen, Charlotte	Combined geno- and phenotyping in DPD diagnostics is of added value in patients with a DPYD variant and decreased DPD enzyme activity